




Research Article

OSU-T315 as an Interesting Lead Molecule for Novel B Cell-Specific Therapeutics

Kristien Van Belle ^{1,2}, Jean Herman,^{1,2,3} Mark Waer,^{1,2} Ben Sprangers ^{1,2,4}
and Thierry Louat ^{1,2}

¹Interface Valorisation Platform (IVAP), KU Leuven, 3000 Leuven, Belgium

²Laboratory of Experimental Transplantation, Department of Microbiology & Immunology, KU Leuven, 3000 Leuven, Belgium

³Department of Pediatric Nephrology and Solid Organ Transplantation, University Hospitals Leuven, 3000 Leuven, Belgium

⁴Department of Nephrology, University Hospitals Leuven, 3000 Leuven, Belgium

Correspondence should be addressed to Kristien Van Belle; kristien.van.belle@gmail.com

Received 10 April 2018; Accepted 9 August 2018; Published 12 September 2018

Academic Editor: Peirong Jiao

Copyright © 2018 Kristien Van Belle et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

B cells are pathogenic in various disease processes and therefore represent an interesting target for the development of novel immunosuppressants. In the search for new therapeutic molecules, we utilized an *in vitro* B cell activation assay with ODN2006-stimulated Namalwa cells to screen a chemical library of small molecules for B cell modulating effects. OSU-T315, described as an inhibitor of integrin-linked kinase (ILK), was hereby identified as a hit. On human and murine primary B cells, OSU-T315 potently suppressed the proliferation and the production of antibodies and cytokines upon stimulation, suggesting that ILK could be a promising target in the modulation of B cell activity. Mice with B cell-specific knockout of ILK were generated. Surprisingly, knockout of ILK in murine B cells did not affect B cell function as assessed by several *in vivo* and *ex vivo* B cell assays and did not alter the B cell immunosuppressive activity of OSU-T315. In conclusion, OSU-T315 displays potency as B cell modulator, probably through a mechanism of action independent of ILK, and might serve as lead drug molecule for the development of novel B cell-selective drugs.

1. Introduction

At the present time, there are few B cell-specific immunomodulatory agents available and applicable for clinical purposes and they usually aim for a depletion of B cell population(s). These include monoclonal antibodies directed against B cell surface markers, such as rituximab, ocrelizumab, epratuzumab, or directed against B cell growth factors, such as belimumab, and small molecule agents like Bruton's tyrosine kinase (BTK) inhibitor ibrutinib and the proteasome inhibitor bortezomib. Hence, there is an unmet need for new B cell drugs that aim for a modulation of B cell's activation status. Recently, we described the oligodeoxynucleotide (ODN) 2006-stimulated Namalwa cell line as a relevant, homogeneous, and stable B cell activation model by which

new targets and inhibitors of the B cell activation processes can be identified through flow cytometric analysis of the expression of activation and costimulatory cell surface markers [1]. In search of innovative B cell immunomodulating agents, this assay was chosen to screen a library of chemical agents for inhibitory effects on activated human B cells. The screening allowed us to identify OSU-T315 as a potentially interesting agent to interfere with human B cell activation. This compound is described as targeting ILK with IC_{50} of 600 nM in an *in vitro* radiometric kinase assay [2]. In previous studies, some murine models with targeted deletion of ILK have been generated to investigate the role of ILK in the different cell populations [3–10]. To our knowledge, ILK has not yet been studied for its role in B cell biology which encouraged us to explore ILK's potential as target for B cell

therapeutics by generating mice with B cell-specific genetic deletion of ILK.

2. Materials and Methods

2.1. Cells and Cell Lines. Human B cell line Namalwa (European Collection of Cell Cultures, ECACC, England) was maintained in culture flasks (TPP, Switzerland) as suspension culture in complete RPMI 1640 culture medium at 37°C and 5% CO₂. Blood samples of healthy volunteers were collected at the Red Cross of Mechelen, Belgium. Each donor consents to the use of his blood for research purposes. Human peripheral blood mononuclear cells (PBMCs) were obtained by density gradient centrifugation of the heparinized venous blood over Lymphoprep™ (Axis Shield PoC AS; density 1.077 ± 0.001 g/ml). Highly purified naive peripheral human B cells were separated from fresh human PBMCs using magnetic columns by positive selection using cluster of differentiation (CD) 19 magnetic beads according to the manufacturer's instructions (MACS Miltenyi Biotech, Leiden, The Netherlands). The purity of the isolated primary B cells was ≥95% as analyzed by flow cytometry. Cells were suspended at the desired concentration in complete Dulbecco's modified Eagle's medium (DMEM) culture medium. Single-cell suspensions of murine splenocytes were prepared by manual disruption of total spleens, and highly purified B lymphocytes were isolated by immunomagnetic positive selection according to the manufacturer's instructions (STEMCELL Technologies, EasySep™ Mouse CD19 positive selection kit II, Grenoble, France). The purity of the isolated murine B cells was ≥95% as analyzed by flow cytometry. Cells were suspended at the desired concentration in complete DMEM culture medium.

Complete RPMI 1640 culture medium consisted of RPMI 1640 with 10% foetal calf serum (FCS, HyClone® Thermo Scientific, United Kingdom) and 5 µg/ml gentamicin sulphate. Complete DMEM culture medium consisted of DMEM with 10% heat-inactivated FCS and 5 µg/ml gentamicin sulphate. Cell culture media and gentamicin sulphate were purchased from BioWhittaker® Lonza (Verviers, Belgium).

2.2. Characterization of OSU-T315 via Functional In Vitro Assays with Human Cells. OSU-T315 was purchased from Calbiochem, Merck Millipore (Overijse, Belgium). The measurement of cytotoxicity of OSU-T315 was done on cells of the Namalwa cell line by WST-1 viability assay. The cell proliferation agent WST-1 was purchased from Roche Diagnostics (Mannheim, Germany). OSU-T315 was added at different concentrations to the Namalwa cells. After 48 hours of incubation at 37°C and 5% CO₂, Triton® X-100 (0.5% final; Fluka Biochemika, Buchs, Switzerland) was added in control wells. WST-1 reagent was added, and Namalwa cells were incubated for 2 to 4 hours at 37°C and 5% CO₂. The absorbance of the formazan dye was measured by the EnVision™ 2103 Multilabel Reader (Perkin Elmer, Zaventem, Belgium) at 540 nM.

An initial evaluation of B cell modulatory effects was done on Namalwa cells and on human primary B cells by flow cytometric analysis on the expression of activation and

costimulatory cell surface markers after 24 hours of stimulation with 0.1 µM ODN2006 in presence of compound OSU-T315. Furthermore, OSU-T315 was investigated for its effects on antibody and interleukin (IL) 6 production and B cell proliferation upon activation of human B cells by different stimulatory conditions (0.1 µM ODN2006, Invivogen, Toulouse, France; 1 µM resiquimod, Sigma-Aldrich, Diegem, Belgium; 91 µg/ml TNP-BSA, Biosearch Technologies, Novato, California, USA). For assessment of IL6 production, freshly isolated human CD19⁺ B cells were plated at 50000 cells per well in 220 µl complete DMEM medium and activated by different stimulatory conditions. After 2 days of incubation, supernatant was taken for analysis of IL6 with AlphaLISA human IL6 kit according to the manufacturer's instructions (Perkin Elmer, Zaventem, Belgium). Detection was performed with the EnVision™ 2103 Multilabel Reader (Perkin Elmer, Zaventem, Belgium). For assessment of cell proliferation, freshly isolated human CD19⁺ B cells were plated at 50000 cells per well in 220 µl complete DMEM medium and activated by different stimulatory conditions. 10 µCi ³H thymidine (Perkin Elmer, Zaventem, Belgium) was added in the wells for the last 18 hours of 3 days of incubation. The cells were harvested on glass filter paper (Perkin Elmer, Zaventem, Belgium). After drying, radioactivity was counted in a scintillation counter (TopCount, Perkin Elmer, Zaventem, Belgium). For assessment of immunoglobulin (Ig) production, freshly isolated human CD19⁺ B cells were plated at 25000 cells per well in a 384-well plate (Perkin Elmer, Zaventem, Belgium) in 55 µl complete DMEM medium and activated by different stimulatory conditions. After 7 days of incubation, supernatant was taken for analysis of IgM and IgG with AlphaLISA human IgM and IgG kit according to the manufacturer's instructions (Perkin Elmer, Zaventem, Belgium). Detection was performed with the EnVision™ 2103 Multilabel Reader (Perkin Elmer, Zaventem, Belgium). For human one-way mixed lymphocyte reaction (MLR), freshly isolated human PBMCs were the responder cells and growth-inhibited RPMI 1788 cells served as stimulator cells. To block their proliferation RPMI, 1788 cells were treated with 96 nM mitomycin C (mitomycin C Kyowa®, Takeda Belgium, Brussels, Belgium) for 20 minutes at 37°C. After three washes with RPMI 1640 medium containing antibiotics, the stimulator cells were then diluted at the desired cell concentration in complete RPMI 1640 medium. The responder human PBMCs were cocultivated with the stimulator cells, ratio responder/stimulator of 8/3, in complete RPMI 1640 culture medium for 6 days at 37°C and 5% CO₂. DNA synthesis of the responder cells was assayed by the addition of 10 µCi ³H thymidine (Perkin Elmer, Zaventem, Belgium) during the last 18 hours of culture. The cells were harvested on glass filter paper (Perkin Elmer, Zaventem, Belgium). After drying, radioactivity was counted in a scintillation counter (TopCount, Perkin Elmer, Zaventem, Belgium).

2.3. Generation of Mice with B Cell-Specific Deletion of the ILK Gene. We generated mice with B cell-specific deletion of ILK by means of Cre/LoxP system, a technology to induce site-specific recombination events in genomic DNA.

Transgenic ILK^{flox/flox} C57BL/6 mice and CD19^{Cre/Cre} C57BL/6 mice were kindly provided, respectively, by Prof. Dr. Christa Maes (KU Leuven, Belgium) and Prof. Dr. Jan Cools (KU Leuven, Belgium). We used ILK^{flox/flox} C57BL/6 mice, created by the research group of Prof. Dr. René St.-Arnaud (McGill University and Shriners Hospital for Children, Montreal, Canada), wherein LoxP sites were inserted downstream from exons 4 and 12 at the ILK locus. To delete ILK *in vivo* in B cells, ILK^{flox/flox} C57BL/6 mice were bred with CD19^{Cre/Cre} C57BL/6 mice, wherein the expression of Cre recombinase enzyme is placed under the direction of the CD19 promoter, to create CD19^{Cre/WT}/ILK^{flox/flox} mice. Animal care was in accordance with the guidelines for laboratory animals from the KU Leuven, and all experiments were approved by the Ethical Committee for Animal Science of KU Leuven (ethical committee, P075-2010 and P107-2015).

Screening of DNA obtained from murine tail for the inheritance of the floxed ILK gene was performed by polymerase chain reaction (PCR) using the following primers: ILK Jax sense (primer sequence 5' GACCAGGTGGCAGAGGTAAG 3'; Sigma-Aldrich, Diegem, Belgium) and ILK Jax anti-sense (primer sequence 5' GCTTTGTCCACAGGCATCTC 3'; Sigma-Aldrich, Diegem, Belgium). The final concentrations of the components in the PCR mix for floxed ILK were as follows: 25 U/ml GoTaq[®] G2 Flexi DNA polymerase (Promega), 1x Green GoTaq[®] Flexi buffer (Promega), 2 mM MgCl₂, 200 μM dNTPs, 0.4 μM oligonucleotide primers, and 1 μl of DNA sample for total volume of 25 μl. DNAs were amplified for 35 cycles (95°C for 30 seconds, 58°C for 30 seconds, and 72°C for 40 seconds) in GeneAmp[®] PCR System 9700 (Applied Biosystems). The size of the WT ILK allele was 245 base pair (bp) and of the floxed ILK allele was 270 bp (Figure 1(a)). Inheritance of the CD19-Cre transgene was determined by SYBR Green dye-based real-time PCR (RT-PCR) using the following primers: CD19-Cre sense (primer sequence 5' GCGGTCTGGCAGTAAAACTATC 3'; Sigma-Aldrich, Diegem, Belgium) and CD19-Cre anti-sense (primer sequence 5' GTGAAACAGCATTGCTGTC ACTT 3'; Sigma-Aldrich, Diegem, Belgium). The final concentrations of the components in the PCR mix for CD19-Cre were as follows: 1x SYBR[®] Green PCR master mix (Applied Biosystems, Halle, Belgium), 0.8 μM oligonucleotide primers, and 1 μl of DNA sample for total volume of 20 μl. DNAs were amplified with the same program as for the identification of floxed ILK allele(s) in StepOnePlus RT-PCR System (Applied Biosystems, Halle, Belgium). A band of 100 bp indicated the mice with a CD19-Cre allele. Distinction between the homozygous and the heterozygous CD19-Cre mice was done by flow cytometry on murine peripheral blood (Figure 1(b)). Murine blood cells were stained with FITC-labelled anti-murine CD19 (Biolegend, ImTec Diagnostics N.V., Antwerp, Belgium) and PE/Cy5-labelled anti-murine CD45R/B220 (Biolegend, ImTec Diagnostics N.V., Antwerp, Belgium) and analyzed with the 3-color Becton Dickinson FACSCalibur apparatus. CD45R/B220, commonly used as a pan-B cell marker, was included in the double staining to allow visualization of B cells in the blood

of mice with lowered (heterozygous CD19-Cre genotype) or completely deleted (homozygous CD19-Cre genotype) expression of CD19. Using both PCR and flow cytometry, we were able to select the mice of interest for our investigations: ILK wild type (WT) mice CD19^{WT/WT}/ILK^{flox/flox} and ILK knockout (KO) mice CD19^{Cre/WT}/ILK^{flox/flox}. We used in our studies mice with CD19^{Cre/WT}/ILK^{flox/flox} genotype with a partial deletion of CD19 as our ILK KO mice rather than the ones with CD19^{Cre/Cre}/ILK^{flox/flox} genotype with a complete deletion of CD19, because, as reported, complete abrogation in expression of CD19 in mice causes defective late B cell differentiation and decreased Ig responses [11, 12].

2.4. Protein Detection and Western Blot Analysis. B cell-specific deletion of ILK in CD19^{Cre/WT}/ILK^{flox/flox} mice was confirmed by Western blot analysis (Figure 1(c)). Murine splenocytes and highly purified B lymphocytes were lysed, and proteins were separated on NuPAGE[®] Novex[®] 4–12% Bis-Tris gel (Invitrogen[™], Thermo Fisher Scientific, Niederlebert, Germany) and electrotransferred onto polyvinylidene fluoride membrane (Invitrogen[™], Thermo Fisher Scientific, Niederlebert, Germany) and incubated with specific antibodies. Immunoreactive proteins were detected by Bio-Rad Imager (Bio-Rad Laboratories N.V., Temse, Belgium) and normalized to the β-actin content. The used antibodies were monoclonal rabbit anti-ILK (4G9; 1/1000; Cell Signaling Technology[®], Bioké, Leiden, The Netherlands), monoclonal rat anti-CD20 (AISB12; 1/500; Affymetrix[®], eBioscience[®], Vienna, Austria), anti-β-actin (I-19; 1/1000, Santa Cruz Biotechnology, Heidelberg, Germany), and polyclonal (goat anti-rabbit, rabbit anti-goat, and rabbit anti-rat) Ig/HRP (Dako, Heverlee, Belgium).

2.5. TNP-BSA In Vivo Assay. Mice were stimulated with T cell-dependent antigen TNP-BSA, a 2,4,6-trinitrophenyl hapten conjugated with bovine serum albumin (50 μg per mice), solved in complete Freund's adjuvant (Sigma-Aldrich, Diegem, Belgium) by subcutaneous injection. The blood was collected by eye puncture before stimulation and on days 7, 10, 14, 21, and 28 poststimulation. On day 28, the mice underwent for a second time stimulation with TNP-BSA and blood samples were taken on days 35 and 42. Analysis of anti-TNP IgM and IgG in the collected sera was done by ELISA procedure in prepared 96-well ELISA plates (coated overnight at 4°C with 5 μg/ml TNP-BSA in phosphate-buffered saline (PBS)) with sheep anti-mouse IgG (H/L):horse radish peroxidase (HRP) and with goat anti-mouse IgM:HRP (Bio-Rad AbD Serotec, Oxford, United Kingdom), respectively. Peroxidase activity was detected by adding 3,3',5,5'-tetramethylbenzidine liquid substrate (Sigma-Aldrich, Diegem, Belgium). Reaction was stopped by adding 1 M HCl. Optical absorbance was measured by the ELISA reader at 450 nM.

2.6. TNP-Ficoll In Vivo Assay. Mice were immunized intraperitoneally with T cell-independent antigen TNP-Ficoll, a 2,4,6-trinitrophenyl hapten conjugated with Ficoll (25 μg per mice), solved in PBS. The blood was collected by eye puncture before stimulation and on days 5, 7, 10, 14, and




FIGURE 1: Identification of mice with B cell-specific deletion of ILK. Mice with B cell-specific deletion of ILK were identified through PCR (a) and flow cytometry (b) and Western blot (c). (a) DNA from the tail was amplified by PCR and then separated and visualized on 2% agarose gel to identify the mice with floxed ILK genes: L: TrackIt™ 100 bp DNA ladder; WT: ILK^{WT/WT}; H: ILK^{flox/WT}; and F: ILK^{flox/flox}. (b) Identification of mice with CD19^{WT/WT}, CD19^{Cre/WT}, or CD19^{Cre/Cre} genotype was done by flow cytometric analysis on the blood that was double-stained with CD19 (FITC) and CD45R/B220 (PE/Cy5). Mice with CD19^{Cre/Cre} genotype did not display CD19 on the outer surface of the B cells. CD19^{Cre/WT} mice still expressed CD19 on the outer surface of the B cells, but at a lower density than CD19^{WT/WT} mice which consequently translated in a lower MFI compared to CD19^{WT/WT} mice. The similar percentages of gated CD45R/B220⁺ cells with equal MFI demonstrated that there was no loss in the B cell population in CD19^{Cre/WT} mice and CD19^{Cre/Cre} mice compared to CD19^{WT/WT} mice. (c) Western blot was performed on splenocytes and on splenic B cells from mice identified as being ILK wild type (WT, CD19^{WT/WT}/ILK^{flox/flox}) or ILK knockout (KO, CD19^{Cre/WT}/ILK^{flox/flox}). High expression of ILK was observed in the splenocytes of WT and KO mice, but ILK was not detected in the B lymphocytes of the latter.

TABLE 1: *In vitro* phenotypic characterization of OSU-T315 on Namalwa.

<i>In vitro</i> analysis	IC ₅₀ (nM)	SEM (nM)
Flow cytometry		
CD40	270	15
CD69	630	150
CD70	740	55
CD80	240	90
CD83	620	70
CD86	300	95
WST-1	4600	125

Namalwa cells were stimulated with 0.1 μ M ODN2006 in the presence of different concentrations of OSU-T315 and were analyzed 24 hours later by flow cytometry. The cytotoxicity of OSU-T315 on Namalwa cells was assessed by the WST-1 assay after 48 hours of incubation of the cells with different concentrations of the compound. Data are the means with SEM of 3 independently performed experiments.

21 poststimulation. Analysis of anti-TNP IgM in the collected sera was done by ELISA procedure in prepared 96-well ELISA plates (coated overnight at 4 °C with 5 μ g/ml TNP-Ficoll in PBS), as described above.

2.7. *In Vivo* Xenoantibody Assay with BHK-570 Cells. Mice were stimulated with intraperitoneal injection of baby hamster kidney (BHK)-570 cells (LGC Standard, ATCC®, Molsheim, France; 5.10⁶ cells in RPMI-medium, 200 μ l per mice), and the production of IgM and IgG against the hamster cells was analyzed on days 3, 5, 7, and 10 postimmunization. For analysis of the IgM and IgG titer in the murine sera, 5.10⁵ BHK-570 cells were dispatched per well in a 96-well V-bottom plate and 5 μ l of serum sample was added. After incubation of 30 minutes on ice, BHK-570 cells were washed two times with PBS. Secondary antibody (goat anti-mouse IgM antibody-PE or goat anti-mouse IgG antibody-FITC, Biolegend, ImTec Diagnostics N.V. Antwerp, Belgium) was added and incubated for 30 minutes on ice and protected from light. After 3 washes with PBS, IgM and IgG were assessed by flow cytometry with the 3-color Becton Dickinson FACSCalibur apparatus. Ig titer is expressed as mean fluorescence intensity (MFI).

2.8. *Ex Vivo* Murine B Cell Activation Assays. Murine splenic B cells were activated by 5 μ g/ml lipopolysaccharide (LPS), 0.3 μ M ODN1826, or 1 μ M resiquimod. After 2 days of incubation, supernatant was taken for analysis of IL6 and TNF α with AlphaLISA murine IL6 and TNF α kits according to the manufacturer's instructions (Perkin Elmer, Zaventem, Belgium). The proliferation rate of the murine B cells was measured 3 days of poststimulation by adding 10 μ Ci ³H thymidine (Perkin Elmer, Zaventem, Belgium) in the wells for the last 18 hours of incubation. The cells were harvested on glass filter paper (Perkin Elmer, Zaventem, Belgium). After drying, radioactivity was counted in a scintillation counter (TopCount, Perkin Elmer, Zaventem, Belgium). After 7 days of incubation, supernatant was taken for analysis of IgM and IgG with AlphaLISA murine IgM and IgG kits

according to the manufacturer's instructions (Perkin Elmer, Zaventem, Belgium).

2.9. Statistical Analysis. Statistical analyses for different experiments were performed using GraphPad Prism 5.00 for Windows (GraphPad Software, San Diego, California, USA). Data are plotted as mean with SEM. The *p* values were calculated by two-tailed Student's *t*-test. *p* values less than 0.05 are considered as significant.

3. Results

3.1. OSU-T315 Inhibits *In Vitro* Human and Murine B Cell Activation. A collection of chemical agents was screened in our B cell activation assay using ODN2006-stimulated Namalwa cells [1]. Compound OSU-T315 demonstrated potent inhibitory activity on the upregulation of cell surface markers CD40, CD69, CD70, CD80, CD83, and CD86 on Namalwa cells without affecting viability as measured by WST-1 (Table 1). OSU-T315 was also able to suppress in a dose-dependent manner the upregulation of cell surface markers CD69, CD70, CD80, and CD86 on ODN2006-stimulated human primary B cells with an IC₅₀ around 0.5 μ M for each marker (Figure 2). In addition, the production of IgM, IgG, and IL6 by purified human B cells in response to ODN2006 stimulation was significantly decreased by OSU-T315 (Figure 3(a-c)). OSU-T315 inhibited also the *in vitro* proliferation of activated B cells with comparable efficacy (Figure 3(d)). The average IC₅₀ value in the IgG assay was 0.2 μ M, and in the IgM, IL6, and proliferation assays, the average IC₅₀ values were 0.5 μ M. The inhibition of B cells' activation by OSU-T315 is not restricted to Toll-like receptor (TLR) 9 pathway since B cell activation marker induction, IgM, IgG, and IL6 secretion were also impaired when B cells were stimulated by resiquimod (average IC₅₀: CD69 = 1.5 μ M, CD70 = 0.6 μ M, CD80 = 0.8 μ M, and CD86 = 0.9 μ M; IgM = 0.4 μ M, IgG = 0.3 μ M, and IL6 = 1 μ M; Figure 3(a-c)). OSU-T315 displayed less potency in the B cell proliferation assay (Figure 3(d)), probably because resiquimod is a relatively moderate stimulator of B cell proliferation. OSU-T315 inhibited also TNP-BSA-triggered B cell proliferation (Figure 3(d)) with an IC₅₀ value of 0.6 μ M. Inhibitory effect by OSU-T315 was also noticed in the TNP-BSA-induced IgM, IgG, and IL6 production with IC₅₀ values of 1 μ M, 1 μ M, and 1.5 μ M, respectively (Figure 3(a-c)). TNP-BSA was not able to induce a significant upregulation of the investigated cell surface markers. In the one-way mixed MLR assay, that evaluates the proliferation of human PBMCs, OSU-T315 proved to be much less effective (average IC₅₀ = 3.5 μ M) compared to its potency to inhibit the proliferation of human B cells under different stimulatory conditions. This indicates that the inhibitory activity of OSU-T315 is more specific for B lymphocytes as the responder cells in the MLR assay are essentially T cells. OSU-T315 was also active on murine primary B cells as the production of IgM and IgG after stimulation with ODN1826, resiquimod, or LPS was suppressed at comparable potency as in human (average IC₅₀ for the three stimuli: IgM = 0.2 μ M, IgG = 0.2 μ M). OSU-T315 inhibited as well




FIGURE 2: Effect of OSU-T315 on activation and costimulatory cell surface markers after TLR9-mediated stimulation of human B cells. Purified human primary B cells were stimulated with $0.1 \mu\text{M}$ ODN2006 in the presence of different concentrations of OSU-T315 and were analyzed 24 hours later by flow cytometry. Plotted data are the means with SEM of 3 independently performed experiments.

LPS-triggered proliferation (average $\text{IC}_{50} = 0.2 \mu\text{M}$) and LPS-induced production of IL6 (average $\text{IC}_{50} = 0.1 \mu\text{M}$) and TNF α (average $\text{IC}_{50} = 0.5 \mu\text{M}$). The obtained data from the phenotypic *in vitro* assays show that OSU-T315 has potential as a B cell inhibitor.

3.2. ILK Is Not a Key Kinase in B Cell Activation Pathway.

OSU-T315 is reported as an ILK inhibitor with an IC_{50} of $0.6 \mu\text{M}$ in an *in vitro* radiometric kinase assay [2]. Our preliminary results with OSU-T315 suggest that ILK could be a promising target in the modulation of B cell activity. In previous studies, some murine models with targeted deletion of ILK have been created to tackle the role of ILK in the different cell populations, including T cells. To our knowledge, ILK has not yet been studied for its role in B cell biology. We generated mice with B cell-specific genetic deletion of ILK to investigate whether the suppressive effect of OSU-T315 on human and murine primary B cells is mediated by ILK and to validate the involvement of ILK in B cell activation pathways. First, we evaluated the effect of ILK deletion on murine B cells *in vivo*. Wild type (WT) mice and knockout (KO) mice with B cell-specific deletion of ILK were stimulated with ODN1826, and plasmatic levels of IL6 and TNF α were compared. Surprisingly,

there was no significant difference in the level of IL6 and TNF α between ILK WT mice and ILK KO mice (Figure 4). Unexpectedly, IgM production was even higher in ILK KO mice compared to ILK WT mice after immunization with T-independent antigen TNP-Ficoll (Figure 5). Similarly, the production of anti-TNP IgM and IgG after stimulation with TNP-BSA, a T-dependent antigen, was not altered in ILK KO mice (Figure 6). Finally, we examined if the B cell-specific deletion of ILK might affect the *in vivo* IgM and IgG production against xenogeneic BHK-570 cells. In this case too, IgM and IgG production was not significantly different between ILK KO mice and ILK WT mice (Figure 7). To clarify the discrepancy between the genetic and pharmacological inhibition of ILK, OSU-T315 was assessed on murine ILK KO B cells in *ex vivo* models. Here again, the B cell-specific deletion of ILK did not impair the antibody production after ODN1826, resiquimod, or LPS stimulation (Figure 8), but, remarkably, OSU-T315 was as efficient in ILK KO B cells as in ILK WT B cells (Table 2 and Figure 9). The production of cytokines and the proliferation (Figure 10) were not substantially altered by a deleted expression of ILK in the B lymphocytes after LPS challenge, but, again, OSU-T315 remained active on ILK KO B cells (Table 2 and Figure 11).




FIGURE 3: Effect of OSU-T315 on antibody and IL6 production and on human B cell proliferation. Highly purified human primary B cells were activated by different stimulators (0.1 μ M ODN2006, 1 μ M resiquimod, or 91 μ g/ml TNP-BSA). Analysis of IgM (a) and IgG (b) was performed after 7 days of incubation, IL6 (c) was analyzed after 2 days of incubation, and proliferation (d) was measured by 3 H thymidine incorporation after 3 days of incubation. Plotted data are the means with SEM of 3 independently performed experiments.




FIGURE 4: ODN1826 *in vivo* assay on mice with B cell-specific ILK deletion. The production of IL6 (a) and TNF α (b) was measured two hours poststimulation in the plasma of ILK WT mice (black, 3 mice) and ILK KO mice (grey, 3 mice).

4. Discussion

B cells play a central role in the development of cancer [13], autoimmune disorders [14–16], transplant rejection

[17–21], and graft versus host disease [22–24] and therefore represent an attractive immune cell population for the development of novel immunosuppressant agents. Using our validated *in vitro* B cell activation assay [1]




FIGURE 5: IgM production after TNP-Ficoll immunization in mice with B cell-specific ILK deletion. Anti-TNP IgM production was measured by ELISA over time in the sera of ILK WT mice (black, 6 mice) and ILK KO mice (grey, 6 mice). Plotted data are the means with SEM from one representative of two independently performed experiments (* $p < 0.05$; ** $p < 0.01$).




FIGURE 6: Antibody production after TNP-BSA immunization in mice with B cell-specific ILK deletion. The level of anti-TNP IgM (a) and IgG (b) was measured by ELISA over time in the sera of ILK WT mice (black, 8 mice) and ILK KO mice (grey, 8 mice). TNP-BSA challenges are indicated with reversed triangles. Plotted data are the means with SEM from one representative of two independently performed experiments.




FIGURE 7: Xenoantibody production against BHK-570 cells in mice with B cell-specific ILK deletion. IgM (a) and IgG (b) production was measured by flow cytometry in the sera of ILK WT mice (black, 3 mice) and ILK KO mice (grey, 3 mice) after immunization with BHK-570 cells. Plotted data are the means with SEM.




FIGURE 8: *Ex vivo* antibody production by murine splenic WT or ILK KO B lymphocytes upon activation by different stimuli. Freshly isolated splenic B cells from an ILK WT (black) mouse and an ILK KO (grey) mouse underwent stimulation with ODN1826 ($0.3 \mu\text{M}$), resiquimod ($1 \mu\text{M}$), or LPS ($5 \mu\text{g/ml}$), and production of IgM (a) and IgG (b) was measured after 7 days. Unstimulated B cells from ILK WT and ILK KO mouse produce by average 30 ng/ml IgM and 9 ng/ml IgG. Plotted data are the means with SEM of sextuplets. The graphics show data from one representative of the two independently performed experiments.

TABLE 2: *In vitro* phenotypic characterization of OSU-T315 on splenic B cells from wild type mice and mice with B cell-specific deletion of ILK.

Stimulus	Readout	Wild type B cells		ILK KO B cells	
		IC ₅₀ (nM)	SEM (nM)	IC ₅₀ (nM)	SEM (nM)
ODN1826	IgM	215	21	220	10
	IgG	200	75	135	40
Resiquimod	IgM	235	30	200	20
	IgG	215	65	125	15
LPS	IgM	230	65	210	90
	IgG	235	65	180	100
	IL6	80	20	60	15
	TNF α	470	130	690	150
	Proliferation	225	55	105	35

Murine B cells were stimulated with $0.3 \mu\text{M}$ ODN1826, $1 \mu\text{M}$ resiquimod, or $5 \mu\text{g/ml}$ LPS in the presence of different concentrations of OSU-T315. After 7 days of incubation, supernatant was taken for analysis of IgM and IgG. LPS-induced production of IL6 and TNF α was measured after 2 days of incubation. The proliferation rate of LPS-activated murine B cells was measured by ^3H thymidine incorporation after 3 days of incubation. Data are the means with SEM of 2 independently performed experiments.

and various *in vitro* tests, we demonstrated that OSU-T315 influences human B cell function. The weak effect of OSU-T315 in human MLR suggests a rather B cell-specific mode of action.

OSU-T315 is described as ILK inhibitor (IC₅₀ is 600 nM in an *in vitro* radiometric kinase assay [2]) modelled from the scaffold that docks into AKT-binding site, but was originally designed to specifically disrupt the interaction of AKT with its binding site on ILK [25]. AKT needs to be phosphorylated on Thr-308 and on Ser-473 for its complete activation. In literature, Western blot analysis on the phosphorylation of AKT on Ser-473 versus Thr-308 in PC-3 cells, a human prostate cancer cell line, and in MDA-MB-231 cells, a human breast cancer cell line, demonstrated that OSU-T315 selectively suppressed AKT phosphorylation on Ser-473, not on Thr-308, in a dose-dependent manner and this was accompanied by parallel decreases in the phosphorylation levels of GSK3 β and MLC, two downstream targets of ILK [2]. Together, the findings suggested that OSU-T315 might mediate Ser-473 AKT dephosphorylation through inhibition of ILK or through interaction with ILK.

Other small molecules have been explored for their inhibitory activity against ILK, such as KP-392 [26] (also called KP-SD-1), a first generation inhibitor, QLT0267




FIGURE 9: Inhibitory activity of OSU-T315 on Ig production by splenic WT or ILK KO B lymphocytes upon activation by different stimuli. Freshly isolated splenic B cells from an ILK WT (black) mouse and an ILK KO (grey) mouse underwent stimulation with ODN1826 ($0.3 \mu\text{M}$), resiquimod ($1 \mu\text{M}$), or LPS ($5 \mu\text{g/ml}$), and production of IgM (a) and IgG (b) was measured after 7 days. Plotted data are the means with SEM of sextuplets. The graphics show data from one representative of the two independently performed experiments.

[27, 28], a second generation inhibitor, and QLT0254 [29], a derivate of QLT0267 (Quadralogic Technologies Inc., Vancouver, Canada). QLT0267 is characterized as a potent ILK antagonist that inhibits the kinase activity of ILK with IC_{50} of 26 nM (IC_{50} QLT0254 is 300 nM) in a cell-free assay using highly purified recombinant ILK [29, 30]. QLT0267 seemed very specific when assessed in a panel of cell-free recombinant kinase assays against 150 protein kinases [27, 29]. However, some conflicting observations have raised doubt about QLT0267's ILK selectivity. Immortalized murine ILK^{-/-} and ILK^{fl/fl} fibroblasts, cultured under 2D or 3D cell culture conditions, were exposed to QLT0267 and radiation [31]. A significantly lower basal cell survival of ILK^{-/-} fibroblasts demonstrated a higher susceptibility of these ILK-deficient fibroblasts to QLT0267 compared to ILK-expressing ILK^{fl/fl} fibroblasts. Radiosensitivity of both ILK^{-/-} fibroblasts and ILK^{fl/fl} fibroblasts was equally enhanced by QLT0267.

Moreover, QLT0267 did not reverse ILK-mediated radiosensitization of mutant FaDu cells (a human epithelial cell line from a squamous cell carcinoma of the hypopharynx) that were transfected with a constitutively active form of ILK [31]. These findings give a strong indication of possible extra target of compound QLT0267, and further investigations are warranted.

ILK is an evolutionarily conserved and ubiquitously expressed protein and is assumed to play an essential role in the cell-matrix interactions and in the regulation of cellular processes such as growth, proliferation, survival, differentiation, migration, invasion, and angiogenesis [32]. Increased protein levels and activity of ILK have been associated with the oncogenesis and tumour progression of many types of malignancies (the prostate, ovary, breast, colon, pancreas, stomach, and liver), indicating that ILK represents a potential target for new cancer treatments [2], [33–35]. Whether ILK




FIGURE 10: *Ex vivo* IL6 and TNF α production and proliferation of murine splenic WT or ILK KO B lymphocytes stimulated by LPS. Freshly isolated splenic B cells from an ILK WT (black) mouse and an ILK KO (grey) mouse underwent stimulation with LPS (5 μ g/ml). The production of IL6 (a) and TNF α (b) was measured after 2 days and the proliferation (c) after 3 days. Unstimulated B cells from ILK WT and ILK KO mouse produce by average 0.005 ng/ml IL6 and 0.002 ng/ml TNF α and have a CPM value of 75. Plotted data are the means with SEM of sextuplets. The graphics show data from one representative of the three independently performed experiments.

functions as a protein serine/threonine kinase remains subject of ongoing discussions. The principal argument that ILK is a pseudokinase (thus, functions rather as a scaffold protein and displays no catalytic activity) is based on the primary structure of its unusual protein kinase domain at the C-terminal part, which exhibits similarity to serine/threonine kinases, but lacks specific, highly conserved motifs which are considered to be obligatory for catalytic function [36–38]. It is relevant, but it is not sufficient to conclude that ILK does not function as kinase. After all, functional kinases CASK and VRK3 also have similar deficiencies in canonical residues in their catalytic domains [39]. And several experimental *in vitro* studies have shown that recombinant, highly purified ILK is able to phosphorylate specific substrates such as AKT (on Ser-473) and GSK β [37]. On the other hand, murine ILK-deficient fibroblasts [3], chondrocytes [40], or keratinocytes [41] did not show changes in AKT or GSK3 β phosphorylation, implying that ILK does not function as a kinase in these models or can be replaced by others. In *in vivo* studies with *Caenorhabditis elegans* worms and *Drosophila* flies, it was observed that kinase dead ILK mutants rescued the severe phenotypes caused by ILK deletion in both species, indicating ILK functions as a scaffold protein and not as a kinase in invertebrates [38]. Up to the current time, several discrepancies remain unsolved, especially the issue whether ILK is a bona fide kinase or a pseudokinase. Genetic knockout approaches (with siRNA or with Cre/LoxP method) can deliver further clarification about the relevance

and functional role(s) of ILK in the different species, cell types, and biological contexts. A complete deletion of ILK leads to lethality in mice [3], *Xenopus laevis* frogs [42], *Drosophila* flies [43], and *Caenorhabditis elegans* worms [44], emphasizing its importance in embryogenesis and tissue homeostasis. Using the Cre/LoxP recombination system, the mouse ILK-encoding gene has been deleted in several cell types and organs (fibroblasts [3], immortalized macrophages [4], vascular endothelial cells [5], vascular smooth muscle cells [6], chondrocytes [7], heart [8], and mammary epithelial cells [9]). The role of ILK in T cells has been studied using a T cell-specific deletion of ILK, Lck-Cre⁺/ILK^{fllox/fllox} mice [10]. These mice showed neither gross developmental abnormalities nor thymus defects. Thymocytes from the T cell-specific ILK KO mice were phenotypically indistinguishable from control WT thymocytes, but there was enhanced susceptibility to cell death upon stress conditions like serum deprivation. ILK deletion did not affect *in vitro* T cell proliferation. However, ILK-deficient T cells showed an aberrant response to the chemokines CXCL12 and CCL19, indicating that ILK might have a role in leukocyte chemotaxis and immune cell trafficking [10]. To further characterize the role of ILK in B cell biology, we generated B cell-specific ILK KO mice. In these mice and using various B cell stimulation experiments, the absence of the ILK gene did not reveal a suppressive effect in various B cell phenomena such as ODN1826-induced IL6 or TNF α production, TNP-hapten-induced antibody production, and xenoantibody




FIGURE 11: Inhibitory activity of OSU-T315 on cytokine production and proliferation of splenic WT or ILK KO B lymphocytes stimulated by LPS. Freshly isolated splenic B cells from an ILK WT (black) mouse and an ILK KO (grey) mouse underwent stimulation with LPS ($5 \mu\text{g/ml}$). The production of IL6 (a) and TNF α (b) was measured after 2 days and the proliferation (c) after 3 days. Plotted data are the means with SEM of sextuplets. The graphics show data from one representative of the two independently performed experiments.

production. When using B cells from these mice *ex vivo*, no alterations were observed either. Moreover, addition of inhibitor OSU-T315 to ILK WT B cells and ILK KO B cells resulted in a very comparable repression in cellular proliferation and production of antibodies, IL6 and TNF α . Deletion of ILK protein did not diminish the activity of OSU-T315. Our data indicate that ILK is not critical for murine B cell activation, and that OSU-T315 exerts its B cell inhibitory activity through a mechanism independent of ILK.

In conclusion, we demonstrate that OSU-T315 represents an interesting lead to develop new B cell-specific immunosuppressants for human use even if its precise mechanism of action is not yet fully characterized. Involvement of ILK in these processes is not fully supported by our data obtained in mice that suggest that OSU-T315 has a target besides ILK, and that ILK is not a critical regulator of B cell function in murine B cells.

Abbreviations

BHK: Baby hamster kidney
 CD: Cluster of differentiation
 DMEM: Dulbecco's modified Eagle's medium
 FCS: Foetal calf serum
 Ig: Immunoglobulin

IL: Interleukin
 ILK: Integrin-linked kinase
 KO: Knockout
 LPS: Lipopolysaccharide
 MFI: Mean fluorescence intensity
 MLR: Mixed lymphocyte reaction
 ODN: Oligodeoxynucleotide
 PBMC: Peripheral blood mononuclear cell
 PBS: Phosphate-buffered saline
 PCR: Polymerase chain reaction
 TLR: Toll-like receptor
 TNP: 2,4,6-Trinitrophenyl hapten
 WT: Wild type.

Data Availability

The data that support the findings of this study are available from the corresponding author Kristien Van Belle upon reasonable request.

Disclosure

Manuscript is based on the thesis of the first author performed at Interface Valorisation Platform (IVAP), KU

Leuven (https://lirias.kuleuven.be/bitstream/123456789/581894/1/Kristien_Van_Belle_PhDthesis_FINAL.pdf).

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

Acknowledgments

Research reported in this publication was supported by the Industriel Onderzoeksfonds, KU Leuven, KP/12/2010.

References

- [1] K. Van Belle, J. Herman, L. Boon, M. Waer, B. Sprangers, and T. Louat, "Comparative in vitro immune stimulation analysis of primary human B cells and B cell lines," *Journal of Immunology Research*, vol. 2016, Article ID 5281823, 9 pages, 2016.
- [2] S.-L. Lee, E. C. Hsu, C. C. Chou et al., "Identification and characterization of a novel integrin-linked kinase inhibitor," *Journal of Medicinal Chemistry*, vol. 54, no. 18, pp. 6364–6374, 2011.
- [3] T. Sakai, S. Li, D. Docheva et al., "Integrin-linked kinase (ILK) is required for polarizing the epiblast, cell adhesion, and controlling actin accumulation," *Genes & Development*, vol. 17, no. 7, pp. 926–940, 2003.
- [4] A. A. Troussard, N. M. Mawji, C. Ong, A. Mui, R. St.-Arnaud, and S. Dedhar, "Conditional knock-out of integrin-linked kinase demonstrates an essential role in protein kinase B/Akt activation," *Journal of Biological Chemistry*, vol. 278, no. 25, pp. 22374–22378, 2003.
- [5] E. B. Friedrich, E. Liu, S. Sinha et al., "Integrin-linked kinase regulates endothelial cell survival and vascular development," *Molecular and Cellular Biology*, vol. 24, no. 18, pp. 8134–8144, 2004.
- [6] B. Ho and M. P. Bendeck, "Integrin linked kinase (ILK) expression and function in vascular smooth muscle cells," *Cell Adhesion & Migration*, vol. 3, no. 2, pp. 174–176, 2009.
- [7] L. Terpstra, J. Prud'homme, A. Arabian et al., "Reduced chondrocyte proliferation and chondrodysplasia in mice lacking the integrin-linked kinase in chondrocytes," *The Journal of Cell Biology*, vol. 162, no. 1, pp. 139–148, 2003.
- [8] G. E. Hannigan, J. G. Coles, and S. Dedhar, "Integrin-linked kinase at the heart of cardiac contractility, repair, and disease," *Circulation Research*, vol. 100, no. 10, pp. 1408–1414, 2007.
- [9] N. Rooney and C. H. Streuli, "How integrins control mammary epithelial differentiation: a possible role for the ILK-PINCH-Parvin complex," *FEBS Letters*, vol. 585, no. 11, pp. 1663–1672, 2011.
- [10] E. Liu, S. Sinha, C. Williams et al., "Targeted deletion of integrin-linked kinase reveals a role in T-cell chemotaxis and survival," *Molecular and Cellular Biology*, vol. 25, no. 24, pp. 11145–11155, 2005.
- [11] P. Engel, L. J. Zhou, D. C. Ord, S. Sato, B. Koller, and T. F. Tedder, "Abnormal B lymphocyte development, activation, and differentiation in mice that lack or overexpress the Cd19 signal transduction molecule," *Immunity*, vol. 3, no. 1, pp. 39–50, 1995.
- [12] R. C. Rickert, K. Rajewsky, and J. Roes, "Impairment of T-cell-dependent B-cell responses and B-1 cell development in CD19-deficient mice," *Nature*, vol. 376, no. 6538, pp. 352–355, 1995.
- [13] A. L. Shaffer III, R. M. Young, and L. M. Staudt, "Pathogenesis of human B cell lymphomas," *Annual Review of Immunology*, vol. 30, no. 1, pp. 565–610, 2012.
- [14] K. Yanaba, J. D. Bouaziz, T. Matsushita, C. M. Magro, E. W. St.Clair, and T. F. Tedder, "B-lymphocyte contributions to human autoimmune disease," *Immunological Reviews*, vol. 223, no. 1, pp. 284–299, 2008.
- [15] C. S. Hampe, "B cells in autoimmune diseases," *Scientifica*, vol. 2012, Article ID 215308, 18 pages, 2012.
- [16] P. H. Carter and Q. Zhao, "Clinically validated approaches to the treatment of autoimmune diseases," *Expert Opinion on Investigational Drugs*, vol. 19, no. 2, pp. 195–213, 2010.
- [17] M. R. Clatworthy, "Targeting B cells and antibody in transplantation," *American Journal of Transplantation*, vol. 11, no. 7, pp. 1359–1367, 2011.
- [18] J. Durand and E. Chiffolleau, "B cells with regulatory properties in transplantation tolerance," *World Journal of Transplantation*, vol. 5, no. 4, pp. 196–208, 2015.
- [19] K. Y. Shiu and A. Dorling, "Optimising long-term graft survival: establishing the benefit of targeting B lymphocytes," *Clinical Medicine*, vol. 14, Supplement_6, pp. s84–s88, 2014.
- [20] K. Y. Shiu, L. McLaughlin, I. Rebollo-Mesa et al., "B-lymphocytes support and regulate indirect T-cell alloreactivity in individual patients with chronic antibody-mediated rejection," *Kidney International*, vol. 88, no. 3, pp. 560–568, 2015.
- [21] V. Zarkhin, L. Li, and M. Sarwal, "'To B or not to B?' B-cells and graft rejection," *Transplantation*, vol. 85, no. 12, pp. 1705–1714, 2008.
- [22] H. Nakasone, B. Sahaf, and D. B. Miklos, "Therapeutic benefits targeting B-cells in chronic graft-versus-host disease," *International Journal of Hematology*, vol. 101, no. 5, pp. 438–451, 2015.
- [23] S. Sarantopoulos, B. R. Blazar, C. Cutler, and J. Ritz, "Reprint of: B cells in chronic graft-versus-host disease," *Biology of Blood and Marrow Transplantation*, vol. 21, no. 2, pp. S11–S18, 2015.
- [24] A. Shimabukuro-Vornhagen, M. J. Hallek, R. F. Storb, and M. S. von Bergwelt-Baildon, "The role of B cells in the pathogenesis of graft-versus-host disease," *Blood*, vol. 114, no. 24, pp. 4919–4927, 2009.
- [25] T.-M. Liu, Y. Ling, J. A. Woyach et al., "OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells," *Blood*, vol. 125, no. 2, pp. 284–295, 2015.
- [26] J. Liu, P. C. Costello, N. A. Pham et al., "Integrin-linked kinase inhibitor KP-392 demonstrates clinical benefits in an orthotopic human non-small cell lung cancer model," *Journal of Thoracic Oncology*, vol. 1, no. 8, pp. 771–779, 2006.
- [27] M. N. Younes, S. Kim, O. G. Yigitbasi et al., "Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer," *Molecular Cancer Therapeutics*, vol. 4, no. 8, pp. 1146–1156, 2005.
- [28] M. N. Younes, O. G. Yigitbasi, Y. D. Yazici et al., "Effects of the integrin-linked kinase inhibitor QLT0267 on squamous cell carcinoma of the head and neck," *Archives of Otolaryngology – Head & Neck Surgery*, vol. 133, no. 1, pp. 15–23, 2007.
- [29] C. Y. F. Yau, J. J. Wheeler, K. L. Sutton, and D. W. Hedley, "Inhibition of integrin-linked kinase by a selective small

- molecule inhibitor, QLT0254, inhibits the PI3K/PKB/mTOR, Stat3, and FKHR pathways and tumor growth, and enhances gemcitabine-induced apoptosis in human orthotopic primary pancreatic cancer xenografts,” *Cancer Research*, vol. 65, no. 4, pp. 1497–1504, 2005.
- [30] A. A. Troussard, P. C. McDonald, E. D. Wederell et al., “Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival,” *Cancer Research*, vol. 66, no. 1, pp. 393–403, 2006.
- [31] I. Eke, F. Leonhardt, K. Storch, S. Hehlhans, and N. Cordes, “The small molecule inhibitor QLT0267 radiosensitizes squamous cell carcinoma cells of the head and neck,” *PLoS One*, vol. 4, no. 7, article e6434, 2009.
- [32] M. Widmaier, E. Rognoni, K. Radovanac, S. B. Azimifar, and R. Fassler, “Integrin-linked kinase at a glance,” *Journal of Cell Science*, vol. 125, no. 8, pp. 1839–1843, 2012.
- [33] G. Hannigan, A. A. Troussard, and S. Dedhar, “Integrin-linked kinase: a cancer therapeutic target unique among its ILK,” *Nature Reviews Cancer*, vol. 5, no. 1, pp. 51–63, 2005.
- [34] P. C. McDonald, A. B. Fielding, and S. Dedhar, “Integrin-linked kinase—essential roles in physiology and cancer biology,” *Journal of Cell Science*, vol. 121, no. 19, pp. 3121–3132, 2008.
- [35] N. Cordes, “Overexpression of hyperactive integrin-linked kinase leads to increased cellular radiosensitivity,” *Cancer Research*, vol. 64, no. 16, pp. 5683–5692, 2004.
- [36] I. Eke, S. Hehlhans, and N. Cordes, “There’s something about ILK,” *International Journal of Radiation Biology*, vol. 85, no. 11, pp. 929–936, 2009.
- [37] G. E. Hannigan, P. C. McDonald, M. P. Walsh, and S. Dedhar, “Integrin-linked kinase: not so ‘pseudo’ after all,” *Oncogene*, vol. 30, no. 43, pp. 4375–4385, 2011.
- [38] S. A. Wickström, A. Lange, E. Montanez, and R. Fässler, “The ILK/PINCH/parvin complex: the kinase is dead, long live the pseudokinase!,” *The EMBO Journal*, vol. 29, no. 2, pp. 281–291, 2010.
- [39] A. P. Kornev and S. S. Taylor, “Pseudokinases: functional insights gleaned from structure,” *Structure*, vol. 17, no. 1, pp. 5–7, 2009.
- [40] C. Grashoff, A. Aszódi, T. Sakai, E. B. Hunziker, and R. Fässler, “Integrin-linked kinase regulates chondrocyte shape and proliferation,” *EMBO Reports*, vol. 4, no. 4, pp. 432–438, 2003.
- [41] K. Lorenz, C. Grashoff, R. Torka et al., “Integrin-linked kinase is required for epidermal and hair follicle morphogenesis,” *The Journal of Cell Biology*, vol. 177, no. 3, pp. 501–513, 2007.
- [42] T. Yasunaga, M. Kusakabe, H. Yamanaka, H. Hanafusa, N. Masuyama, and E. Nishida, “Xenopus ILK (integrin-linked kinase) is required for morphogenetic movements during gastrulation,” *Genes to Cells*, vol. 10, no. 4, pp. 369–379, 2005.
- [43] C. G. Zervas, S. L. Gregory, and N. H. Brown, “Drosophila integrin-linked kinase is required at sites of integrin adhesion to link the cytoskeleton to the plasma membrane,” *The Journal of Cell Biology*, vol. 152, no. 5, pp. 1007–1018, 2001.
- [44] A. C. Mackinnon, H. Qadota, K. R. Norman, D. G. Moerman, and B. D. Williams, “C. elegans PAT-4/ILK functions as an adaptor protein within integrin adhesion complexes,” *Current Biology*, vol. 12, no. 10, pp. 787–797, 2002.